Cerevel Therapeutics Holdings, Inc.(CERE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CERE Cerevel Therapeutics Holdings, Inc.

停牌 11-22 17:37:51 EST

44.96

+0.00

0.00%

最高44.96	最低44.96	成交量0.00
今开44.96	昨收44.96	日振幅0.00%
总市值81.91亿	流通市值34.99亿	总股本1.82亿
成交额6.79亿	换手率0.00%	流通股本7,782万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CERE","market":"US","secType":"STK","nameCN":"Cerevel Therapeutics Holdings, Inc.","latestPrice":44.96,"timestamp":1722456000000,"preClose":44.96,"halted":3,"volume":0,"delay":0,"floatShares":77824202,"shares":182194722,"eps":-2.736044,"marketStatus":"停牌","marketStatusCode":4,"change":0,"latestTime":"11-22 17:37:51 EST","open":44.96,"high":44.96,"low":44.96,"amount":678996554.61312,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.736044,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1732323600000},"adr":0,"adjPreClose":44.96,"volumeRatio":0},"requestUrl":"/m/hq/s/CERE","defaultTab":"news","newsList":[{"id":"2478435940","title":"更新版 3-艾伯维将以 14 亿美元收购阿尔茨海默氏症疗法开发商 Aliada","url":"https://stock-news.laohu8.com/highlight/detail?id=2478435940","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478435940?lang=zh_cn&edition=full","pubTime":"2024-10-28 20:15","pubTimestamp":1730117755,"startTime":"0","endTime":"0","summary":"更新版 3-艾伯维将以 14 亿美元收购阿尔茨海默氏症疗法开发商 Aliada重写第 3 段，在第 8 段增加分析师评论。路透10月28日 - 艾伯维ABBV.N周一表示，将以14亿美元现金收购Aliada Therapeutics公司，获得这家私营疗法开发商的阿尔茨海默病候选药物，因为这家美国制药商正在加强对神经科学的关注。艾伯维表示，Aliada 的 ALIA-1758 是一种处于早期开发阶段的治疗阿尔茨海默氏症的抗体，有可能成为同类最佳疗法。Aliada 的交易预计将于今年年底完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241028:nL4T3M40WD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985320562.USD","LU0256863902.USD","LU0203345920.USD","LU0965509010.AUD","IE00BVYPNV92.GBP","LU0661504455.SGD","IE0004445239.USD","LU0029864427.USD","IE00BVYPNW00.USD","LU0256863811.USD","LU0545039389.USD","BK4532","LU0965509101.SGD","BK4534","LU0943347566.SGD","BK4533","BK4550","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU0122379950.USD","LU1023059063.AUD","BIIB","LU0738911758.USD","LU0234572021.USD","ABBV","LU0211327993.USD","CERE","LU0820561909.HKD","IE00B894F039.SGD","LU0203347892.USD","LU0708994859.HKD","IE00BJT1NW94.SGD","LU0912757837.SGD","LU0795875086.SGD","BK4566","LU0114720955.EUR","LU0198837287.USD","BK4585","LU0417517546.SGD","LU0965508806.USD","IE00B3PB1722.GBP","LU0861579265.USD","IE00BJJMRZ35.SGD","LU0553294199.USD","IE00BGHQF631.EUR","LU0109394709.USD","IE00BDGV0183.EUR","LU1003077747.HKD","IE00B19Z9P08.USD"],"gpt_icon":0},{"id":"2478031489","title":"更新版 2-艾伯维将以 14 亿美元收购阿尔茨海默氏症疗法开发商 Aliada","url":"https://stock-news.laohu8.com/highlight/detail?id=2478031489","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478031489?lang=zh_cn&edition=full","pubTime":"2024-10-28 20:15","pubTimestamp":1730117755,"startTime":"0","endTime":"0","summary":"更新版 2-艾伯维将以 14 亿美元收购阿尔茨海默氏症疗法开发商 Aliada第 2 段增加了背景，全文增加了细节。路透10月28日 - 艾伯维ABBV.N周一表示，将以14亿美元现金收购Aliada Therapeutics公司，获得这家私营疗法开发商的阿尔茨海默病候选药物，因为这家美国制药商正加大对神经科学的关注。\" 美国疾病控制和预防中心表示，预计阿尔茨海默氏症患者人数将翻一番，从2020年的690万人增加到2060年的近1400万人。Aliada 的交易预计将于今年年底完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241028:nL4S3M40WD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800379.SGD","LU0211328371.USD","BK4585","LU0256863811.USD","LU0820561818.USD","LU0689472784.USD","LU0203345920.USD","LU0198837287.USD","LU0417517546.SGD","LU0029864427.USD","IE0004445239.USD","LU0708994859.HKD","BK4588","IE0002141913.USD","LU0820561909.HKD","LU0965509101.SGD","BK4533","BK4139","ABBV","IE00B42XCP33.USD","BK4566","LU0949170772.SGD","LU0965508806.USD","CERE","LU0965509010.AUD","LU1003077747.HKD","BK4534","LU0738911758.USD","BK4550","BK4581","LU0170899867.USD","LU1023059063.AUD","IE00BGHQF631.EUR","LU0122379950.USD","LU0128525929.USD","LU0211327993.USD","LU0553294199.USD","LU0158827948.USD","LU0203347892.USD","LU0114720955.EUR","LU0661504455.SGD","IE00BSNM7G36.USD","LU0456855351.SGD","LU0310799852.SGD","IE0009355771.USD","LU0545039389.USD","IE00B4R5TH58.HKD","LU0943347566.SGD","LU0234572021.USD","LU0861579265.USD"],"gpt_icon":0},{"id":"2472528327","title":"更新版 2-减肥药市场升温，Kailera Therapeutics 公司净赚 4 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2472528327","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472528327?lang=zh_cn&edition=full","pubTime":"2024-10-01 19:08","pubTimestamp":1727780917,"startTime":"0","endTime":"0","summary":"更新版 2-减肥药市场升温，Kailera Therapeutics 公司净赚 4 亿美元第 2 段和第 10 段增加了有关管理层的细节，第 3-5 段增加了有关减肥药物市场的背景资料。路透10月1日 - Kailera Therapeutics 是一家新创企业，希望在蓬勃发展的抗肥胖疗法市场占有一席之地，该公司于本周二成立，获得了来自四家投资者的 4 亿美元投资。Kailera 正在开发几种用于体重管理的注射和口服疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241001:nL4T3LD0VW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4568","IE00BVYPNW00.USD","LU0109394709.USD","BK4578","LU0211328371.USD","03145","IE00B4R5TH58.HKD","BK4139","LU0820561909.HKD","LU2087621335.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","00016","BK1216","LU0310800379.SGD","LENZ","LU0456855351.SGD","LU0985320562.USD","LU0170899867.USD","LU1003077747.HKD","LU0203345920.USD","CERE","LU0198837287.USD","LU0943347566.SGD","BK1559","LU1244550221.USD","LU1066053197.SGD","SG9999010078.USD","SUHJY","IE00B2B36J28.USD","LU0114720955.EUR","LU0689472784.USD","03121","IE00BVYPNV92.GBP","BK4581","LU0820561818.USD","IE00BKVL7J92.USD","IE0009355771.USD","ABBV","80016","BK4585","LU2088748376.SGD","LU0795875169.SGD","GILD","LU2226123227.USD","LU2088748293.HKD","LU1839511570.USD","LU1316543674.SGD","LU2226123490.SGD"],"gpt_icon":0},{"id":"2472022293","title":"更新版 3-凯莱拉获得 4 亿美元早期融资，加入减肥药行列","url":"https://stock-news.laohu8.com/highlight/detail?id=2472022293","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472022293?lang=zh_cn&edition=full","pubTime":"2024-10-01 19:08","pubTimestamp":1727780917,"startTime":"0","endTime":"0","summary":"更新版 3-凯莱拉获得 4 亿美元早期融资，加入减肥药行列添加第 4 和第 8 段 CEO 访谈中的评论Niket  Nishant. 路透10月1日 - Kailera Therapeutics公司于本周二成立，作为最新成立的初创公司，该公司试图在蓬勃发展的抗肥胖症疗法市场分一杯羹，并罕见地获得了4亿美元的早期融资。凯莱拉表示，其最先进的候选药物KAI-9531已在中国肥胖症和2型糖尿病的中期试验中取得了 \"令人信服的结果\"。上周上市的减肥药开发商BioAge Labs BIOA.O ，截至周一，其股价比首次公开发行价高出近16%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241001:nL4T3LD0VW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0820561818.USD","LU1066053197.SGD","LU0689472784.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0820561909.HKD","LU0158827948.USD","LU2226123490.SGD","LU1003077747.HKD","LU0456855351.SGD","SG9999010052.SGD","BK4139","LU0889565916.HKD","IE00BSNM7G36.USD","IE00BDGV0183.EUR","IE0009355771.USD","SUHJY","03121","ABBV","LU0198837287.USD","03145","00016","LU0029864427.USD","LU2226123227.USD","LU1316543674.SGD","LU0795875169.SGD","IE00BKVL7J92.USD","IE00B19Z3581.USD","IE00BVYPNV92.GBP","LU0256863902.USD","LU0985320562.USD","LU0170899867.USD","IE00B2B36J28.USD","LU1839511570.USD","BK4588","LU2087621335.USD","LU2088748293.HKD","LU0949170772.SGD","BK1559","IE00BVYPNW00.USD","LU0234570918.USD","SG9999010078.USD","CERE","80016","LU1430594728.SGD","LU0203345920.USD","IE00B4R5TH58.HKD","BK4581","LU0795875086.SGD","GILD"],"gpt_icon":0},{"id":"2455660927","title":"Cerevel Therapeutics Holdings Inc   预计每股亏损61美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455660927","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455660927?lang=zh_cn&edition=full","pubTime":"2024-07-29 23:55","pubTimestamp":1722268546,"startTime":"0","endTime":"0","summary":"   * Cerevel Therapeutics Holdings Inc    预计在7月31日公布截至2024年6月30日的业绩时，季度收入将没有变化()    *    * LSEG分析师对Cerevel Therapeutics Holdings Inc的平均预期是每股亏损61美分。* 华尔街对 Cerevel Therapeutics Holdings Inc 的 12 个月目标价中位数为 45.00 美元，高于其上次收盘价 44.62 美元。7月29日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CERE"],"gpt_icon":0},{"id":"2446560609","title":"Cerevel Therapeutics Holdings, Inc.盘中异动 股价大涨7.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446560609","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446560609?lang=zh_cn&edition=full","pubTime":"2024-06-28 03:42","pubTimestamp":1719517369,"startTime":"0","endTime":"0","summary":"北京时间2024年06月28日03时42分，Cerevel Therapeutics Holdings, Inc.股票出现异动，股价急速拉升7.21%。Cerevel Therapeutics Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.72%。Cerevel Therapeutics Holdings, Inc.公司简介：Cerevel Therapeutics Holdings Inc致力于揭示大脑的奥秘，以治疗神经科学疾病。Cerevel Therapeutics正在推进其当前的研发计划，同时通过内部研究工作，外部合作或潜在的收购来探索新的方式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628034249941f1ded&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628034249941f1ded&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CERE"],"gpt_icon":0},{"id":"2446825825","title":"Cerevel Therapeutics Holdings, Inc.盘中异动 股价大跌5.02%报39.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446825825","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446825825?lang=zh_cn&edition=full","pubTime":"2024-06-25 23:36","pubTimestamp":1719329771,"startTime":"0","endTime":"0","summary":"北京时间2024年06月25日23时36分，Cerevel Therapeutics Holdings, Inc.股票出现波动，股价大幅跳水5.02%。Cerevel Therapeutics Holdings, Inc.股票所在的生物技术行业中，整体涨幅为1.98%。Cerevel Therapeutics Holdings, Inc.公司简介：Cerevel Therapeutics Holdings Inc致力于揭示大脑的奥秘，以治疗神经科学疾病。Cerevel Therapeutics正在推进其当前的研发计划，同时通过内部研究工作，外部合作或潜在的收购来探索新的方式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062523361196816ab0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062523361196816ab0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CERE","BK4139","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cerevel.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0.0878},{"period":"1year","weight":0.8472},{"period":"ytd","weight":0.0604}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cerevel Therapeutics Holdings, Inc.是特拉华州的一家公司。该公司是一家临床阶段的生物制药公司，将对疾病相关生物学和大脑神经回路的深刻理解与先进的化学和中枢神经系统（中枢神经系统）靶向受体选择性药理学相结合，以发现和设计新的疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.087399},{"month":2,"riseRate":0.5,"avgChangeRate":-0.01137},{"month":3,"riseRate":0.5,"avgChangeRate":0.043276},{"month":4,"riseRate":0.75,"avgChangeRate":0.024279},{"month":5,"riseRate":0.25,"avgChangeRate":-0.03235},{"month":6,"riseRate":0.75,"avgChangeRate":0.235861},{"month":7,"riseRate":0.25,"avgChangeRate":0.004466},{"month":8,"riseRate":0.4,"avgChangeRate":0.022596},{"month":9,"riseRate":0,"avgChangeRate":-0.047536},{"month":10,"riseRate":0.5,"avgChangeRate":0.109092},{"month":11,"riseRate":0.75,"avgChangeRate":0.067582},{"month":12,"riseRate":1,"avgChangeRate":0.234479}],"exchange":"NASDAQ","name":"Cerevel Therapeutics Holdings, Inc.","nameEN":"Cerevel Therapeutics Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cerevel Therapeutics Holdings, Inc.(CERE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cerevel Therapeutics Holdings, Inc.(CERE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cerevel Therapeutics Holdings, Inc.,CERE,Cerevel Therapeutics Holdings, Inc.股票,Cerevel Therapeutics Holdings, Inc.股票老虎,Cerevel Therapeutics Holdings, Inc.股票老虎国际,Cerevel Therapeutics Holdings, Inc.行情,Cerevel Therapeutics Holdings, Inc.股票行情,Cerevel Therapeutics Holdings, Inc.股价,Cerevel Therapeutics Holdings, Inc.股市,Cerevel Therapeutics Holdings, Inc.股票价格,Cerevel Therapeutics Holdings, Inc.股票交易,Cerevel Therapeutics Holdings, Inc.股票购买,Cerevel Therapeutics Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cerevel Therapeutics Holdings, Inc.(CERE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cerevel Therapeutics Holdings, Inc.(CERE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}